This document discusses regulatory aspects of stability testing in Europe. It provides an overview of the objectives and requirements for stability testing of pharmaceutical ingredients and products containing them. The key points are:
1) Stability testing aims to establish appropriate storage conditions and shelf lives by evaluating how quality varies over time under different environmental factors like temperature, humidity, and light.
2) Testing is required for both active ingredients and finished products to justify storage conditions, retest periods, and shelf lives. It involves evaluating physical, chemical, microbial, and other changes over time under various conditions.
3) Guidelines from the European CPMP and ICH specify design, conduct, evaluation, and reporting of stability studies to support regulatory submissions in
CGMP guidelines, CFR, CDER and CBER, PIC/S, Environment control in pharma industry, plant layout, maintenance of sterile area, Clean room classification, Environmental monitoring, Types of contaminants in pharma industry & Good Warehousing Practices.
CGMP guidelines, CFR, CDER and CBER, PIC/S, Environment control in pharma industry, plant layout, maintenance of sterile area, Clean room classification, Environmental monitoring, Types of contaminants in pharma industry & Good Warehousing Practices.
Validation: Validation is a documented program that provides high degree of assurance that a specific process, method or system consistently produces a result meeting pre-determined acceptance criteria.
Manufacturing Control Systems. J R Controls provides control systems for the manufacturing industry. A typical control system will monitor the progress of parts through the manufacturing and finishing process.
Expiry date , calculation of yields, production record review, change controlSantosh kumar
The responsibility of the pharmaceutical manufacturer is that the drug product should have the stated potency and therapeutic effectiveness till the end of the shelf life of the product This shelf life should be based on t
This presentation gives an idea about extractable and leachables, Analytical techniques used for conducting studies. importance of conducting E&L studies.
In Process Quality Control Tests (IPQC) For Parenteral or Sterile Dosage FormsSagar Savale
These are the tests performed between QA and QC and provides for the authorization of approved raw materials for manufacturing based on actual laboratory testing generally called as IPQC such as physical, chemical, microbiologic and biologic tests.
Validation: Validation is a documented program that provides high degree of assurance that a specific process, method or system consistently produces a result meeting pre-determined acceptance criteria.
Manufacturing Control Systems. J R Controls provides control systems for the manufacturing industry. A typical control system will monitor the progress of parts through the manufacturing and finishing process.
Expiry date , calculation of yields, production record review, change controlSantosh kumar
The responsibility of the pharmaceutical manufacturer is that the drug product should have the stated potency and therapeutic effectiveness till the end of the shelf life of the product This shelf life should be based on t
This presentation gives an idea about extractable and leachables, Analytical techniques used for conducting studies. importance of conducting E&L studies.
In Process Quality Control Tests (IPQC) For Parenteral or Sterile Dosage FormsSagar Savale
These are the tests performed between QA and QC and provides for the authorization of approved raw materials for manufacturing based on actual laboratory testing generally called as IPQC such as physical, chemical, microbiologic and biologic tests.
This slide show reflects general considerations of Bio-availability & Bio-equivalence studies for orally administered drugs. The presentation also accommodates US - FDA's approach and specific recommendations for such studies.
The dissolution test is an important means of assuring the continuing performance of non-solution orally administered drug products. The development of a dissolution test procedure is briefly discussed in USP general information chapter In Vitro and In Vivo Evaluation of Dosage Forms 1088, whereas general information chapter Validation of Compendial Procedures 1225 gives limited validation information for dissolution testing. Neither of these two chapters provides a level of detail and focus sufficient for dissolution testing. In 2001, a Stimuli article provided an initial rationale and discussion of content for a new general information chapter. The new chapter, The Dissolution Procedure: Development and Validation 1092, was intended to supplement the information in 1088 and 1225 and provided step-by-step detail for development and validation as well as offering information on new technology and equipment. In 2006, the chapter became official with the Second Supplement to USP 29–NF 24 (2–4).
The General Chapters—Dosage Forms Expert Committee 2010–2015 placed the review and possible revision of The Dissolution Procedure: Development and Validation 1092 on its work plan for the 2010–2015 revision cycle (2011) .
Drug Regulations has prepared this presentation based on the proposed chapter.
Dissolution, factors affecting drug dissolution, methods to evaluate dissolution, advantages and disadvantages, recent approaches--these are the topics covered in this presentation.
Stability Testing.pptx ,M.PHARM,1ST year ,1st semesterManshiRana2
Stability testing of dosage forms is an important aspect of pharmaceutical development and manufacturing. It involves evaluating the physical, chemical, and microbiological attributes of a dosage form over a specific period of time under various storage conditions.
The purpose of stability testing is to ensure the efficacy, quality and safety of the drug throughout its shelf life.
.
SCOPE OF STABILITY TESTING Provide evidence as to how the quality of drug product varies with time.
Determine recommended storage conditions.
Establish shelf life for the drug product.
Establish quality of a drug product or substance .
Determine container and closure system suitability .
THE PRESENTATIONS DESCRIBES THE ICH GUIDELINE FOR RESIDUAL SOLVENTS i.e Q3C.
IT contains the basic of ICH and the complete description about the ICH guideline Q3C and its classification,limits,acceptance criteria in Pharma industries and the standards.
#Pharmaceuticalguideline
#medicine
#healthandmedicine
This document is intended to provide guidance for registration applications on the content and qualification of impurities in new drug substances produced by chemical syntheses and not previously registered in a region or member state.
This guideline is a revised of the ICHQ1A –stability data package for new drug substance /DRUG PRODUCT .The [urpose of guideline to define stability data package that sufficient for a registration application within the 3 regions of EU ,JAPAN & USA & to maintain the quality of drug products, in relation to safety , efficacy & acceptability throughout the propose shelf life.
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
How to Create Map Views in the Odoo 17 ERPCeline George
The map views are useful for providing a geographical representation of data. They allow users to visualize and analyze the data in a more intuitive manner.
Palestine last event orientationfvgnh .pptxRaedMohamed3
An EFL lesson about the current events in Palestine. It is intended to be for intermediate students who wish to increase their listening skills through a short lesson in power point.
2024.06.01 Introducing a competency framework for languag learning materials ...Sandy Millin
http://sandymillin.wordpress.com/iateflwebinar2024
Published classroom materials form the basis of syllabuses, drive teacher professional development, and have a potentially huge influence on learners, teachers and education systems. All teachers also create their own materials, whether a few sentences on a blackboard, a highly-structured fully-realised online course, or anything in between. Despite this, the knowledge and skills needed to create effective language learning materials are rarely part of teacher training, and are mostly learnt by trial and error.
Knowledge and skills frameworks, generally called competency frameworks, for ELT teachers, trainers and managers have existed for a few years now. However, until I created one for my MA dissertation, there wasn’t one drawing together what we need to know and do to be able to effectively produce language learning materials.
This webinar will introduce you to my framework, highlighting the key competencies I identified from my research. It will also show how anybody involved in language teaching (any language, not just English!), teacher training, managing schools or developing language learning materials can benefit from using the framework.
This is a presentation by Dada Robert in a Your Skill Boost masterclass organised by the Excellence Foundation for South Sudan (EFSS) on Saturday, the 25th and Sunday, the 26th of May 2024.
He discussed the concept of quality improvement, emphasizing its applicability to various aspects of life, including personal, project, and program improvements. He defined quality as doing the right thing at the right time in the right way to achieve the best possible results and discussed the concept of the "gap" between what we know and what we do, and how this gap represents the areas we need to improve. He explained the scientific approach to quality improvement, which involves systematic performance analysis, testing and learning, and implementing change ideas. He also highlighted the importance of client focus and a team approach to quality improvement.
The Roman Empire A Historical Colossus.pdfkaushalkr1407
The Roman Empire, a vast and enduring power, stands as one of history's most remarkable civilizations, leaving an indelible imprint on the world. It emerged from the Roman Republic, transitioning into an imperial powerhouse under the leadership of Augustus Caesar in 27 BCE. This transformation marked the beginning of an era defined by unprecedented territorial expansion, architectural marvels, and profound cultural influence.
The empire's roots lie in the city of Rome, founded, according to legend, by Romulus in 753 BCE. Over centuries, Rome evolved from a small settlement to a formidable republic, characterized by a complex political system with elected officials and checks on power. However, internal strife, class conflicts, and military ambitions paved the way for the end of the Republic. Julius Caesar’s dictatorship and subsequent assassination in 44 BCE created a power vacuum, leading to a civil war. Octavian, later Augustus, emerged victorious, heralding the Roman Empire’s birth.
Under Augustus, the empire experienced the Pax Romana, a 200-year period of relative peace and stability. Augustus reformed the military, established efficient administrative systems, and initiated grand construction projects. The empire's borders expanded, encompassing territories from Britain to Egypt and from Spain to the Euphrates. Roman legions, renowned for their discipline and engineering prowess, secured and maintained these vast territories, building roads, fortifications, and cities that facilitated control and integration.
The Roman Empire’s society was hierarchical, with a rigid class system. At the top were the patricians, wealthy elites who held significant political power. Below them were the plebeians, free citizens with limited political influence, and the vast numbers of slaves who formed the backbone of the economy. The family unit was central, governed by the paterfamilias, the male head who held absolute authority.
Culturally, the Romans were eclectic, absorbing and adapting elements from the civilizations they encountered, particularly the Greeks. Roman art, literature, and philosophy reflected this synthesis, creating a rich cultural tapestry. Latin, the Roman language, became the lingua franca of the Western world, influencing numerous modern languages.
Roman architecture and engineering achievements were monumental. They perfected the arch, vault, and dome, constructing enduring structures like the Colosseum, Pantheon, and aqueducts. These engineering marvels not only showcased Roman ingenuity but also served practical purposes, from public entertainment to water supply.
The Indian economy is classified into different sectors to simplify the analysis and understanding of economic activities. For Class 10, it's essential to grasp the sectors of the Indian economy, understand their characteristics, and recognize their importance. This guide will provide detailed notes on the Sectors of the Indian Economy Class 10, using specific long-tail keywords to enhance comprehension.
For more information, visit-www.vavaclasses.com
Thesis Statement for students diagnonsed withADHD.ppt
Tushar Ceutics
1. Regulatory Aspects of Stability
Testing in Europe
Presented by: Guided by:
SAGAR SHAH Mrs. RENUKA MISHRA
2. Introduction
• The stability of pharmaceutical ingredient and the
products containing them depends on:
1)The chemical and physical properties of the material
concerned including the excipients and container
system)
2)Environmental factors such as temperature, humidity
and light and their effect on the substance in the
product.
• Some of the types of changes in product that may need
to considered are:
a) Physical changes: Appearance,consistency,clarity of
solution,colour,odour,taste,hardness,disintegration,dissol
ution,pH.
b) Chemical changes: Degradation product formation,
loss of potency, loss of excipients
c) Microbial changes: proliferation of microorganisms in
nonsterile products, maintenance of sterility,presevative
efficacy changes
3. A) To establish the storage condition and retest interval of
active ingredient and storage condition and shelf life for
manufactured product.
B) Part of information can also used to justify overages
included in products for stability reasons.
Committee of proprietary medicinal products(CPMP) indicates
that the objectives of the stability testing is:
“to provide evidence on how the quality of an API or
product varies with time under the influence of a variety of
environment factors such as temperature humidity and light
and enables recommended storage conditions, retest periods
and shelf life. “
Reason for stability studies:
4. Pharmaceutical expert reports
• It is an important tool in regulatory submission in
Europe. it should provide a critical assessment of all
data as given below:
For active ingredient:
• A summary of results and analytical data
• The variability of stability data of drug from different
batches
• Most appropriate storage conditions of API
• The significant degradation products with relevant
information in the pharmacotoxicological expert report.
5. • Discussion of data relating to potential effects of
manufacturing procedure (heating and exposure the
ionizing radiation) on stability of product.
• Assay result of product and degradation products
• A discussion of variability in stability found between
batches of finished product.
• Explanation of calculation data used to estimate the
shelflife.
• A justification of overages in the products indicating
whether thy are because of stability reason or to cover
the manufacturing losses.
• Justification for release and proposed shelflife and
storage conditions.
For Finished Product:
6. There should always interplay between stability
section and other parts of marketing authorization
application. for example, PER may need to discuss
number of items included in development
pharmaceutics section i.e.
• Compatibility of drug substance and excipients
• Effect of pH.
• Dissolution performance of conventional release
products
• A discussion of potential interaction, particularly between
semisolid and liquid product and their container system
• A discussion of particular impurity that could be present
in API,Product;impurity from starting
material,solvents,reagents.
• When a product containing a novel excipient, a full data
is required including stability data of excipient.
7. Sources of information
• The primary source of regulatory requirements in the
European community are the pharmaceutical regulation and
directives.
• There are two primary sites of information. the first is
eudralex at dg3.eudra.org/eudralex,which has all documents
for human medicines that form the rules governing medical
products in the European union in PDF.
• 2nd,the CPMP and ICH draft and adapted guidelines on
European agency for the Evaluation of Medicinal
Products(EMEA)/cpmp home page at www.eudra.org.
8. Guidelines
• The European community's CPMP adopted a guideline on
stability testing in July, 1988 and came in to effect in 1989.
• For a new drug substances and products containing them, it
has been replaced by ICH guidelines and it is expected that all
applications submitted since 1998 will include studies that
have been conducted as per ICH guidelines.
• A revision of the old cpmp stability guideline was adapted in
April 1998 and was in effect in October 1998.
• In the main of ICH guidelines, recent documents also include a
note for guidelines on photo stability testing and another for
new drug product.
9. Data requirements
• For this all analytical methods should be validated. It should
be capable of detecting and quantifying the degradation
products and the interaction products in the finished
products.
• The basic requirements to be included in application on the
stability the active ingredient and the finished products are
summarized below.
For active ingredients:
• Information on the batches tested(including date and place of
manufacturing. Batch size)
• Details of testing methodology, including
normal,stress,accelerated conditions.
10. • Analytical test procedures and their validation data, with reference
to assay and the determination of degradation products.
• Conclusion and Results
• A proposed retest period and storage condition.
For dosage form
• Proposed shelf life including the acceptable limits for impurity or
degradation products
• Batches tested and packaging used
• Study design
• Characteristics studied, including physical, microbiological, chemical
as well as characteristics of the products such as the potency and
the purity, interaction between container and product
• Preservative efficacy and sterility testing
• Evaluation of the test procedure.
11. • For some dosage forms, particular aspects of stability testing
may need to be given particular attention.
• Stability of intravenous additives in the diluents for IV
infusions.
• The stability characteristics of aerosol inhalation( particularly
when it is having Al container with halogenated propellants) .
• Products in the plastic containers will require special
consideration, particularly with respect to protection against
external factors, extraction of material for the polymer or the
release of the material from the polymers,tightness of the
closure etc.
12. Impurities in new active substance
• The ICH guidelines on impurities in new active substance
requires characterization of reoccurring impurities and
degradation products found at or above an apparent level of
0.1%.data may be reported regarding studies undertaken on
an impurities below 0.1%,although this is not normally
required unless the potential impurities are expected to be
unusually potent or toxic or to have pharmacological effect.
Impurities in new medicinal products
• The suggested thresholds are as follow:
13. MAXIMUM DAILY DOSE THRESHOLD FOR REPORTING
<= 1 gm 0.1%
> 1 gm 0.05%
Maximum daily dose Threshold For Identification
< 1 mg 1.0 % or 5 µg total daily intake,
which ever is lowest
1 to 10 mg 0.5% or 20 µg total daily intake,
which ever is lowest
10 mg – 2 gm 0.2% or 2 mg total daily intake,
which ever is lowest
> 2 gm 0.1%
14. Maximum daily dose Threshold For Identification
< 10 mg 1.0 % or 5 µg total daily intake,
which ever is lowest
10 to 100 mg 0.5% or 200 µg total daily
intake, which ever is lowest
>100 mg – 2 gm 0.2% or 2 mg total daily intake,
which ever is lowest
> 2 gm 0.1%
